Next Article in Journal
Upconversion Fluorescence Nanoprobe-Based FRET for the Sensitive Determination of Shigella
Next Article in Special Issue
State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer
Previous Article in Journal
An Innovative Sandwich Type Biosensor towards Sensitive and Selective Monitoring of 2-Arachidonoylglycerol in Human Plasma Samples Using P(β-CD)-AuNPs-DDT as Amplificant Agent: A New Immuno-Platform for the Recognition of Endocannabinoids in Real Samples
Previous Article in Special Issue
Recent Advances in Early Diagnosis of Viruses Associated with Gastroenteritis by Biosensors
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Yu et al. Recent Advances of Mesoporous Silica as a Platform for Cancer Immunotherapy. Biosensors 2022, 12, 109

1
Precision Medicine and Healthcare Research Center, Center for Biotechnology and Biomedicine, Shenzhen Key Laboratory of Gene and Antibody Therapy, State Key Laboratory of Chemical Oncogenomics, State Key Laboratory of Health Sciences and Technology, Tsinghua-Berkeley Shenzhen Institute (TBSI), Institute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China
2
School of Science and Shenzhen Key Laboratory of Flexible Printed Electronics Technology, Harbin Institute of Technology, Shenzhen 518055, China
*
Author to whom correspondence should be addressed.
Biosensors 2022, 12(10), 794; https://doi.org/10.3390/bios12100794
Submission received: 25 May 2022 / Accepted: 22 August 2022 / Published: 27 September 2022
(This article belongs to the Special Issue Advances in Nanomedicines for Disease Diagnosis and Therapeutics)

Additional Affiliation(s)

In the published publication [1], there was an error regarding the affiliation(s) for Albert Yu, Xiaoyong Dai, Zixian Wang, Huaqing Chen, and Laiqiang Huang. In addition to affiliations 1, 2 and 3, the updated affiliations should include: 1. Precision Medicine and Healthcare Research Center, Center for Biotechnology and Biomedicine, Shenzhen Key Laboratory of Gene and Antibody Therapy, State Key Laboratory of Chemical Oncogenomics, State Key Laboratory of Health Sciences and Technology, Tsinghua-Berkeley Shenzhen Institute (TBSI), Institute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China. 2. School of Science and Shenzhen Key Laboratory of Flexible Printed Electronics Technology, Harbin Institute of Technology, Shenzhen 518055, China. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Yu, A.; Dai, X.; Wang, Z.; Chen, H.; Guo, B.; Huang, L. Recent Advances of Mesoporous Silica as a Platform for Cancer Immunotherapy. Biosensors 2022, 12, 109. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Yu, A.; Dai, X.; Wang, Z.; Chen, H.; Guo, B.; Huang, L. Correction: Yu et al. Recent Advances of Mesoporous Silica as a Platform for Cancer Immunotherapy. Biosensors 2022, 12, 109. Biosensors 2022, 12, 794. https://doi.org/10.3390/bios12100794

AMA Style

Yu A, Dai X, Wang Z, Chen H, Guo B, Huang L. Correction: Yu et al. Recent Advances of Mesoporous Silica as a Platform for Cancer Immunotherapy. Biosensors 2022, 12, 109. Biosensors. 2022; 12(10):794. https://doi.org/10.3390/bios12100794

Chicago/Turabian Style

Yu, Albert, Xiaoyong Dai, Zixian Wang, Huaqing Chen, Bing Guo, and Laiqiang Huang. 2022. "Correction: Yu et al. Recent Advances of Mesoporous Silica as a Platform for Cancer Immunotherapy. Biosensors 2022, 12, 109" Biosensors 12, no. 10: 794. https://doi.org/10.3390/bios12100794

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop